Royalty Pharma plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RPRX research report →
Range $66 – $80
Price Chart
About the company
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
- CEO
- Pablo Legorreta
- IPO
- 2020
- Employees
- 100
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on RPRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $30.48B
- P/E
- 40.63
- Fwd P/E
- 12.67
- PEG
- -1.79
- P/S
- 11.55
- P/B
- 4.43
- EV/EBITDA
- 24.92
- Div Yield
- 1.39%
- Gross Margin
- 89.75%
- Op Margin
- 57.14%
- Net Margin
- 25.66%
- ROE
- 9.93%
- ROIC
- 7.76%
Latest fiscal year · YoY change
- Revenue
- $2.38B+5.1%
- Gross Profit
- $2.38B+5.1%
- Op Income
- $1.56B
- Net Income
- $770.95M-10.2%
- EPS
- $2.33+21.4%
- OCF Growth
- -10.1%
- FCF Growth
- -10.1%
- 52W High
- $70.37
- 52W Low
- $37.31
- 50D MA
- $62.11
- 200D MA
- $55.14
- Beta
- 0.41
- RSI (14)
- 63
- Avg Volume
- 3.19M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Royalty Pharma posted another strong quarter with 9% top-line growth and raised 2026 guidance again, while highlighting a robust pipeline and continued capital deployment.· November 4, 2026
- Portfolio Receipts rose 9% in the third quarter to $890 million; Royalty Receipts also grew 9%, with 12% growth year to date.
- Management raised full-year 2026 guidance for the third straight quarter, now expecting Portfolio Receipts of $3.5 billion to $3.55 billion.
- The company deployed about $1.6 billion of capital year to date and returned close to $590 million to shareholders through dividends and buybacks.
- Recent deal activity included $100 million for Mimrylo and $100 million upfront for Zoryve, both described as having blockbuster potential.
- Development-stage portfolio updates were mostly positive, but Novartis' pelacarsen Phase III failure was a disappointment; management said the structure still protects returns.
Third-quarter Portfolio Receipts increased 9% to $890 million, and Royalty Receipts grew 9% in the quarter and 12% year to date. Operating and professional costs were 5.6% of Portfolio Receipts; net interest paid was $167 million; and portfolio cash flow was $673 million, implying a margin of around 76% in the quarter and 82% year to date. Return on invested capital was 14.3% and return on invested equity was 20.2%. Cash and equivalents were $514 million at the end of September, debt was $8.8 billion, leverage was 2.7x total debt to adjusted EBITDA or 2.5x net, and the revolver was undrawn. For 2026, management now expects Portfolio Receipts of $3.5 billion to $3.55 billion, Royalty Receipts growth of around 10% to 11%, operating and professional costs of 5.5% to 6% of Portfolio Receipts, and interest paid of about $350 million to $360 million.
Pablo Legorreta said the quarter reflected strong execution, consistent growth, and attractive returns, and he framed Royalty Pharma as a long-term capital allocator with a durable, low-volatility model. He emphasized that the company is benefiting from powerful industry tailwinds, a broad deal pipeline, and its ability to raise guidance repeatedly while still returning capital. His tone was upbeat and confident, and he repeatedly highlighted the company’s track record and its expanding role in biopharma funding.
Terry Coyne focused on the quality of cash generation and capital flexibility. He said Portfolio Receipts were $890 million in the quarter, portfolio cash flow was $673 million, and margins remained high at around 76% in the quarter and 82% year to date. He also noted $514 million of cash, $8.8 billion of debt, 2.7x leverage, and roughly $4.8 billion of financial flexibility including the revolver and cash generation. On capital allocation, he said the company deployed just over $1.2 billion in the first 9 months and returned about $590 million to shareholders, and he reiterated full-year guidance for receipts, expenses, and interest.
Analysts pressed on Imdelltra economics, pelacarsen/olpasiran risk, competition in therapeutic areas, R&D co-funding, China, private-company deals, AI, and pricing power for ecopipam. Management said Imdelltra’s recent first-line data was ahead of expectations and should expand the opportunity, but they deferred detailed comments on olpasiran until more data is presented. They said competition and more Chinese out-licensing create more opportunities rather than a zero-sum problem, that R&D co-funding is a major growth area with $1 billion announced this year, and that China deployment is already underway through the BeOne/Imdelltra royalty and a local team. On pelacarsen, they said the investment was structured protectively; on ecopipam, they said Teva should have pricing flexibility because it is a first-in-class product in an under-served category.
The call showed solid underlying momentum: recurring royalty receipts are still growing double digits year to date, guidance was raised again, and the portfolio delivered several favorable clinical and regulatory events. Management also pointed to a deep pipeline, active capital deployment, and new growth avenues such as pharma R&D co-funding and China-related royalty opportunities. The company’s high cash conversion, strong returns, and ample liquidity support continued reinvestment and shareholder returns.
The main setback was Novartis' pelacarsen Phase III failure, which led to a noncash impairment charge and reduced one upside component of the portfolio. Management also flagged that milestones and other contractual receipts are expected to decline sharply in 2026, which is part of why top-line growth guidance relies more heavily on recurring royalties. Analysts also pushed on competition, pricing pressure, and whether future pipeline wins may be offset by faster-moving rivals or changing market dynamics in major therapeutic areas.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.7%
- Shares Outstanding
- 445.27M
- Float Shares
- 417.14M
of shares held by institutions
660 13F filers
Buy/sell ratio 0.64. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Morgan Stanley | 41.10M | ▼ 1.83M |
| Capital International Investors | 33.90M | ▼ 1.38M |
| Blackrock, Inc. | 29.12M | ▲ 1.28M |
| Fmr LLC | 19.35M | ▼ 5.16M |
| State Street Corp | 12.95M | ▲ 613.37K |
| Price T Rowe Associates Inc | 11.19M | ▲ 9.26M |
| Swedbank Ab | 10.26M | ▼ 466.01K |
| Vanguard Group Inc | 9.93M | ▼ 1.00M |
| Baillie Gifford & Co | 9.15M | ▼ 863.63K |
| Capital World Investors | 8.76M | ▼ 761.57K |
| Geode Capital Management, LLC | 8.55M | ▲ 488.71K |
| Invesco Ltd. | 7.30M | ▲ 3.07M |
Held by 1,361 ETFs
Biggest fund positions in RPRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Hite Christopher | sell | 100,000 |
| Nov 16, 26 | Coyne Terrance P. | sell | 135,249 |
| Nov 16, 26 | Coyne Terrance P. | sell | 90,165 |
| Nov 16, 26 | Coyne Terrance P. | sell | 7,122 |
| Nov 17, 26 | Coyne Terrance P. | sell | 9,835 |
| Nov 16, 26 | Urist Marshall | sell | 23,592 |
| Nov 16, 26 | Urist Marshall | sell | 1,408 |
| Nov 6, 26 | Coyne Terrance P. | other | 10,000 |
| Nov 6, 26 | Coyne Terrance P. | other | 150,000 |
| Nov 6, 26 | Coyne Terrance P. | other | 15,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RPRX coverage
Recent articles, reports, and earnings notes.
Want a deeper read on RPRX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
RPRX vs. ILMN: Which Stock Should Value Investors Buy Now?
zacks.com · Nov 20
Royalty Pharma plc (RPRX) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
Royalty Pharma PLC $RPRX Shares Sold by Eurizon Capital SGR S.p.A.
defenseworld.net · Nov 16
310,727 Royalty Pharma PLC $RPRX Shares Sold by Alps Advisors Inc.
defenseworld.net · Nov 16
Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE?
fool.com · Nov 15
Royalty Pharma to present at the UBS Global Biopharma Conference
globenewswire.com · Nov 12
Royalty Pharma: Stronger Royalty Growth Supports Further Upside
seekingalpha.com · Nov 12
3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them
247wallst.com · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
